Kimryn Rathmell, M.D., Ph.D.

Director, Division of Hematology and Oncology

Cornelius Abernathy Craig Chair, Department of Medicine

Professor of Medicine and Biochemistry

Research: Molecular studies in renal cell carcinoma

Clinical: Kidney cancer, VHL, hereditary kidney cancers, clinical trials


Hematology and Oncology


M.D. - Stanford University, Stanford, California (1998)

Ph.D. - Stanford University, Stanford, California (1996)

B.A. - University of Northern Iowa, Cedar Falls, Iowa (1991)

B.S. - University of Northern Iowa, Cedar Falls, Iowa (1991)



Fellowship in Hematology/Oncology - University of Pennsylvania, 2003


University of Chicago Medical Center, 1999

Office Address:
2220 Pierce Avenue, Preston Research Building, Room / Suite Suite 777, Nashville, TN 37232

Kimryn Rathmell, M.D., Ph.D.

Research Description 

As the Director of the Division of Hematology and Oncology, I am invested in creating a basic, translational, and clinical program that supports each of our cancer programs. As a genitourinary oncologist, I lead the GU oncology disease group clinical and research program, focusing my own research on renal cell carcinoma. Our laboratory is focused on cancers caused by deregulation of the normal hypoxia response pathway. We use clear cell renal cell carcinoma as a model system because virtually all of these tumors display dysregulation of this pathway. This cancer affects over 60,000 new patients annually in the US. Recent molecular discoveries based on understanding the hypoxia response pathway have led to the development of multiple new lines of treatment for this cancer. Our goal is to identify strategies to improve the treatment of cancers dependent on hypoxia pathway activation, or better ways to detect these cancers earlier. Therefore, our research takes a broad approach using genetic techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.

Clinical Interest 

Areas of Expertise

Medical Oncology
Prostate, Bladder, and Kidney Cancer
Urologic/Genitourinary Cancer


Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
2220 Pierce Avenue
Nashville, TN 37232

Research Keywords 

Renal cell carcinoma

Previous Institution 

University of North Carolina at Chapel Hill

Previous Role/Title 

Associate Professor of Medicine




Sheffield, IA

board and certifications 

Medical Oncology - American Board of Internal Medicine, 2004


Fellowship in Hematology/Oncology - University of Pennsylvania, 2003